Finding dose–volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer
- 1 November 2003
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 69 (2) , 215-222
- https://doi.org/10.1016/j.radonc.2003.08.003
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Late morbidity profiles in prostate cancer patients treated to 79–84 Gy by a simple four-field coplanar beam arrangementInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutionsRadiotherapy and Oncology, 2002
- Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose–volume histograms and normal tissue complication probabilityRadiotherapy and Oncology, 2002
- The radiotherapeutic injury – a complex ‘wound’Radiotherapy and Oncology, 2002
- Correlations between dose–surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Treatment plan evaluation using dose–volume histogram (DVH) and spatial dose–volume histogram (zDVH)International Journal of Radiation Oncology*Biology*Physics, 1999
- Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Prostate target volume variations during a course of radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Estimation of the Incidence of Late Bladder and Rectum Complications After High-Dose (70–78 Gy) Conformal Radiotherapy for Prostate Cancer, Using Dose–Volume HistogramsInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Late rectal bleeding following combined x-ray and proton high dose irradiation for patients with stages T3–T4 prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1993